Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here: https://rb.gy/09bxx

Press releases

January 4, 2024

Immunovia announces financial calendar for financial year 2024

Read press release
November 21, 2023 | REGULATORY

Bulletin from the extraordinary general meeting in Immunovia AB

Read press release
November 9, 2023 | REGULATORY

Immunovia Publishes Interim Report for January-September 2023

Read press release
November 7, 2023

Immunovia successfully completes discovery phase of next-generation test development

Read press release
November 2, 2023

Invitation to Immunovia’s Q3 presentation

Read press release
October 27, 2023 | REGULATORY

CONVENING NOTICE – EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)

Read press release
October 3, 2023 | REGULATORY

Nomination Committee appointed for Immunovia AB (Publ)

Read press release
August 30, 2023 | REGULATORY

Immunovia Publishes Interim Report for January-June 2023

Read press release
August 23, 2023

Invitation to Immunovia’s Q2 presentation

Read press release
July 19, 2023

Immunovia announces updated financial calendar

Read press release
July 11, 2023 | REGULATORY

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

Read press release
June 9, 2023

Chief Executive Officer, Jeff Borcherding, buys Immunovia shares

Read press release
1 2 3 4 28